Community Financial Services Group LLC Has $694,000 Stake in Pfizer Inc. (NYSE:PFE)

Community Financial Services Group LLC lessened its position in Pfizer Inc. (NYSE:PFE) by 30.9% in the fourth quarter, Holdings Channel.com reports. The firm owned 26,141 shares of the biopharmaceutical company’s stock after selling 11,699 shares during the quarter. Community Financial Services Group LLC’s holdings in Pfizer were worth $694,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Retirement Wealth Solutions LLC acquired a new position in shares of Pfizer in the fourth quarter valued at approximately $26,000. Gladius Capital Management LP increased its position in Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 38,015 shares during the period. Teachers Insurance & Annuity Association of America bought a new position in shares of Pfizer during the third quarter valued at $35,000. Joseph Group Capital Management lifted its holdings in shares of Pfizer by 168.3% during the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 771 shares during the period. Finally, Sugar Maple Asset Management LLC bought a new stake in shares of Pfizer in the fourth quarter worth $43,000. 68.36% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on PFE shares. Guggenheim reaffirmed a “buy” rating and set a $33.00 target price on shares of Pfizer in a research report on Monday. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Bank of America reaffirmed a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, UBS Group reduced their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Performance

Shares of Pfizer stock opened at $25.53 on Wednesday. The business has a 50-day simple moving average of $26.28 and a 200 day simple moving average of $27.69. The firm has a market capitalization of $144.69 billion, a price-to-earnings ratio of 18.11, a PEG ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period in the prior year, the firm earned $0.10 earnings per share. Pfizer’s revenue for the quarter was up 24.7% on a year-over-year basis. On average, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.74%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is currently 121.99%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.